ArticleOncotarget2016
XPG rs2296147 T>C polymorphism predicted clinical outcome in colorectal cancer.
Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 5 syntheses or guidelines pooled it, 17 citations in OpenAlex.
- A microRNA binding site polymorphism in the 3' UTR region of VEGF-A gene modifies colorectal cancer risk based on ethnicity: a meta-analysis.Journal of the Egyptian National Cancer Institute · 2022Pooled it
- Association between the XPG gene rs2094258 polymorphism and risk of gastric cancer.Journal of clinical laboratory analysis · 2018Pooled it
- The association between XPG polymorphisms and cancer susceptibility: Evidence from observational studies.Medicine · 2017Pooled it
- High TGF-β1 expression predicts poor disease prognosis in hepatocellular carcinoma patients.Oncotarget · 2017Pooled it
- Predictive value of XPG rs2296147T>C polymorphism on clinical outcomes of cancer patients.Oncotarget · 2016Pooled it
- Nucleotide excision repair pathway gene polymorphisms are associated with risk and prognosis of colorectal cancer.World journal of gastroenterology · 2020Article
- Genetic variants in RPA1 associated with the response to oxaliplatin-based chemotherapy in colorectal cancer.Journal of gastroenterology · 2019Article
- Association ofWorld journal of gastroenterology · 2019Article
- An insight into clinical outcome of XPG polymorphisms in breast cancer.Molecular biology reports · 2018Article
- High expression of ERCC5 predicts a poor prognosis in hepatocellular carcinoma.International journal of clinical and experimental pathology · 2018Article
- Diagnostic and prognostic values of the mRNA expression of excision repair cross-complementation enzymes in hepatitis B virus-related hepatocellular carcinoma.Cancer management and research · 2018Article
- Prognosis and value of preoperative radiotherapy in locally advanced rectal signet-ring cell carcinoma.Scientific reports · 2017Article
- KRAS and VEGF gene 3'-UTR single nucleotide polymorphisms predicted susceptibility in colorectal cancer.PloS one · 2017Article
- Association between genetic variants in theAging · 2016Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Xeroderma pigmentosum group G (XPG), one of key components of nucleotide excision repair pathway (NER), is involved in excision repair of UV-induced DNA damage. Single nucleotide polymorphisms (SNPs) in the XPG gene have been reported to associate with the clinical outcome of various cancer patients. We aimed to assess the impact of four potentially functional SNPs (rs2094258 C>T, rs2296147 T>C, rs751402 G>A, and rs873601 G>A) in the XPG gene on prognosis in colorectal cancer (CRC) patients. A total of 1901 patients diagnosed with pathologically confirmed CRC were genotyped for four XPG polymorphisms. Cox proportional hazards model analysis controlled for several confounding factors was conducted to compute hazard ratios (HRs) and 95% confidence intervals (CIs). Of the four included SNPs, only rs2296147 was shown to significantly affect progression-free survival (PFS) in CRC. Patients carrying rs2296147 CT/TT genotype had a significantly shorter median 10 years PFS than those carrying CC genotype (88.5 months vs. 118.1 months), and an increased progression risk were observed with rs2296147 (HR = 1.324, 95% CI = 1.046-1.667). Moreover, none of the four SNPs were associated with overall survival. In conclusion, our study showed that XPG rs2296147 CT/TT variants conferred significant survival disadvantage in CRC patients in term of PFS. XPG rs2296147 polymorphism could be predictive of unfavorable prognosis of CRC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.